Background: Polycystic ovarian syndrome (PCOS) is a common endocrine disorder that affects the fertility of reproductive-aged women due to high levels of testosterone. Metformin is currently used to treat patients with PCOS in order to improve the biochemical markers of the disease. New studies show that statin medications like simvastatin may prove efficacious with reduction of testosterone levels, and therefore, possibly increase fertility.
Methods: An extensive search of MEDLINE, CINAHL, Web of Science, and EBM Multifiles was conducted. Articles that were not written in the English language and duplicate articles were excluded.
Results: Three studies were identified through the search of literature. The studies showed that simvastatin and metformin therapy do reduce testosterone levels in patients with PCOS. The studies used for this review were of low to very low quality.
Conclusion: Based on current research, utilizing simvastatin and metformin as dual therapies for patients with PCOS should not be recommended. Even though there seems to be some significance to the therapy in decreasing testosterone levels and other biochemical markers of the disease, more high-quality research is necessary to determine the effects of simvastatin plus metformin therapy in polycystic ovarian syndrome patients.
Keywords: simvastatin, anticholesteremic agents, hydroxymethylglutaryl-CoA reductase inhibitors, metformin, polycystic ovarian syndrome
|File name||Date Uploaded||Visibility||File size|